02/08/2018

The FDA approved Zytiga (abiraterone acetate) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC)

The FDA approved Zytiga (abiraterone acetate) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC).

The FDA initially approved abiraterone acetate with prednisone in 2011 for patients with metastatic castration-resistant prostate cancer (CRPC) who had received prior chemotherapy, and expanded the indication in 2012 for patients with metastatic CRPC.  

For more information, click here.